

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Geiben Lynn, *et al.*
SERIAL NUMBER: 10/057,613 **EXAMINER:** Stacy Brown Chen
FILING DATE: January 25, 2002 **ART UNIT:** 1648
FOR: Serpin Drugs for Treatment of HIV Infection and Method of Use Thereof

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the document listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary European Search Report in the corresponding European application number 02731136.4. Accordingly, no fee or certification is believed required.


It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

APPLICANTS: Geiben-Lynn *et al.*
U.S.S.N.: 10/057,613

Please charge any fees that may be due, or credit any overpayment of same, to Deposit
Account No. 50-0311 (Reference No. 23659-501).

Respectfully submitted,


Ivor R. Elrffi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

May 11, 2004

TRA 1917309v1

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/057,613
	Filing Date	01/25/02
	First Named Inventor	Geiben Lynn
	Group Art Unit	1648
	Examiner Name	Stacy Brown Chen
	Attorney Docket Number	23659-501

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A4	5,610,286	3/11/97	Shau et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B3	WO	96/39424	Human Genome Sciences, Inc			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C33	Geiben-Lynn et al. J. Biol. Chem. 2003. 278:1569-74.					
	C34	Jin et al. J. Biol. Chem. 1997. 272:30952-61.					
	C35	Jin et al. 2000. Antioxidant and Redox Regulation of Genes. 381-407 (cover only, full article to follow).					
	C36	Supplementary European Search Report, mailed February 11, 2004.					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.